• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 4/19/24: The Health and Healthcare of Gen-Z, Long-Acting Drugs May Revolutionize HIV Prevention/Treatment & more


The latest news for pharma industry insiders.

What is the Current State of Remote Monitoring in Oncology Clinical Trials?

Survey study of eight biopharma companies aimed to identify how often technology is being used in cancer trials.

Talking About the Generations:The health and healthcare of boomers, Gen Xers, millennials and Gen Zers. Part 4, Gen Z.

Generation Z (1997–2012). Everything on demand, including healthcare.

Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatment

New regimens in development, including once-weekly pills and semiannual shots, could help control the virus in hard-to-reach populations.

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging

GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence, advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health. These latest systems combine high-performance hardware with flexible scalable software to help increase clinicians’ confidence in their diagnostic and treatment determinations.

Coya Therapeutics, Inc. on LinkedIn:

Coya CEO Howard Berman recently sat down with Pharmaceutical Executive's Don Tracy to discuss Coya 302 and its potential for the treatment of #ALS. Watch part 1 of the interview here and stay tuned for part 2: https://lnkd.in/eTGdiBAv

$Coya #CoyaTherapeutics #neurodegenerative

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs